Drugs / SHR6508
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06877247 | Dec 2024 → Apr 2025 | secondary hyperparathyroidism of renal origin | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05221008 | Mar 2022 → Jul 2023 | secondary hyperparathyroidism of renal origin | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06236295 | Feb 2024 → Nov 2025 | secondary hyperparathyroidism of renal origin | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05663411 | Feb → Oct 2023 | secondary hyperparathyroidism of renal origin | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06434961 | Jun 2024 → Sep 2025 | secondary hyperparathyroidism of renal origin | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR6508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06434961 ↗ |